CAR-T Immune Toxicity Linked to Non-Relapse Mortality Risk in Myeloma

(MedPage Today) — Chimeric antigen receptor (CAR) T-cell therapy-associated immune-related adverse events (CirAEs) were associated with a high rate of non-relapse mortality in patients with multiple myeloma, according to a retrospective study…